Next trial for Starpharma
Wednesday, 13 August, 2008
Melbourne's Starpharma has started a new clinical trial of VivaGel to measure the duration of antiviral activity after administration.
VivaGel is a vaginal microbicide aimed at preventing transmission of HIV and genital herpes.
Assessment will be by laboratory assay of vaginal samples collected up to 24 hours after VivaGel application. The study in 12 women will determine the timescale over which VivaGel retains activity against HIV and HSV-2 (genital herpes).
"The value of this short trial is that it provides a potential surrogate for antiviral efficacy of VivaGel in humans ahead of Phase III studies," Starpharma's CEO Dr Jackie Fairley said. "It will also give an indication of just how long before sex you could apply VivaGel to prevent infection."
The study is being conducted at the Centre for Clinical Studies in Melbourne and is funded by the US National Institutes of Health (NIH).
Quitting smoking increases life expectancy even for seniors
Although the benefits of quitting smoking diminish with age, there are still substantial gains...
Stem cell transplants treat blindness in mini pigs
Scientists have successfully transplanted retinas made from stem cells into blind mini pigs,...
Sugary drinks raise cardiovascular disease risk, but occasional sweets don't
Although higher sugar intake raises your risk of certain cardiovascular diseases, consuming sweet...
